Compare Main Street Capital Corporation (MAIN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs TransMedics Group Inc — how do they compare? Main Street Capital Corporation trades at $54.08 (market cap $5.09B), while TransMedics Group Inc trades at $80.68 (market cap $2.74B). The key difference: Main Street Capital Corporation is the larger of the two by market cap, and Main Street Capital Corporation pays a 5.84% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and TransMedics Group Inc for 24 Days on average.
| MAIN | TMDX | |
|---|---|---|
Market Cap | $5.09B | $2.74B |
Volume | 524,060 | 949,331 |
Sector | Financials | Health |
52-Week High | $64.60 | $150.42 |
52-Week Low | $49.63 | $61.99 |
Typical Hold Time | 88 Days | 24 Days |
Enterprise Value | $7.54B | $3.13B |
Dividend Yield | 5.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.305, up 0.23% on the day, with a bearish technical outlook as moving averages and oscillators signal selling pressure. Fundamentally, the company maintains strong profitability with an 80.77% net income margin and a P/E of 10.94, though revenue declined to $592 million in 2025 from $601 million in 2024. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026. The stock pays consistent monthly dividends, with the latest being $0.27 per share.
The investment outlook is cautious; analyst consensus is a 'Hold' with a $58.33 price target, indicating modest upside. Risks include softening earnings, a premium valuation at 1.62x NAV, and sensitivity to interest rates. The bearish technicals and high hold ratings suggest limited near-term catalysts, but the dividend yield near 8% and robust ROE of 14.92% provide income support.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
